Waldenstrom Macroglobulinemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia – Pipeline Review, H2 2016’, provides an overview of the Waldenstrom Macroglobulinemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia

The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Waldenstrom Macroglobulinemia therapeutics and enlists all their major and minor projects

The report assesses Waldenstrom Macroglobulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Amgen Inc.


Aurigene Discovery Technologies Limited

Bayer AG

BeiGene, Ltd.

Calithera Biosciences, Inc.

Celgene Corporation

Genentech, Inc.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

IGF Oncology, LLC.

Incyte Corporation

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Novartis AG

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Vivolux AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Waldenstrom Macroglobulinemia Overview 9

Therapeutics Development 10

Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10

Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11

Waldenstrom Macroglobulinemia - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Waldenstrom Macroglobulinemia - Products under Development by Companies 16

Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

Amgen Inc. 19

arGEN-X BV 20

Aurigene Discovery Technologies Limited 21

Bayer AG 22

BeiGene, Ltd. 23

Calithera Biosciences, Inc. 24

Celgene Corporation 25

Genentech, Inc. 26

Gilead Sciences, Inc. 27

Hutchison MediPharma Limited 28

IGF Oncology, LLC. 29

Incyte Corporation 30

Juno Therapeutics Inc. 31

Karyopharm Therapeutics, Inc. 32

Merck KGaA 33

Millennium Pharmaceuticals Inc 34

Novartis AG 35

Ono Pharmaceutical Co., Ltd. 36

Portola Pharmaceuticals, Inc. 37

Takeda Pharmaceutical Company Limited 38

Vivolux AB 39

Waldenstrom Macroglobulinemia - Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Combination Products 41

Assessment by Target 42

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

(dezapelisib + itacitinib adipate) - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

765IGF-MTX - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

acalabrutinib - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

alisertib - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ARGX-110 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

BGB-3111 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

bortezomib - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

CA-4948 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

carfilzomib - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

CB-839 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

cerdulatinib - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

copanlisib hydrochloride - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

dezapelisib - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

DI-B4 - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

DTRMWXHS-12 - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

entospletinib - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

everolimus - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

HMPL-523 - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

INCB-50465 - Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

itacitinib adipate - Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

ixazomib citrate - Drug Profile 128

Product Description 128

Mechanism Of Action 128

R&D Progress 128

JCAR-015 - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

lenalidomide - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

M-7583 - Drug Profile 156

Product Description 156

Mechanism Of Action 156

R&D Progress 156

ONO-4059 - Drug Profile 157

Product Description 157

Mechanism Of Action 157

R&D Progress 157

oprozomib - Drug Profile 159

Product Description 159

Mechanism Of Action 159

R&D Progress 159

selinexor - Drug Profile 162

Product Description 162

Mechanism Of Action 162

R&D Progress 162

Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

spebrutinib besylate - Drug Profile 181

Product Description 181

Mechanism Of Action 181

R&D Progress 181

TAK-659 - Drug Profile 183

Product Description 183

Mechanism Of Action 183

R&D Progress 183

venetoclax - Drug Profile 184

Product Description 184

Mechanism Of Action 184

R&D Progress 184

VLX-1570 - Drug Profile 194

Product Description 194

Mechanism Of Action 194

R&D Progress 194

Waldenstrom Macroglobulinemia - Dormant Projects 196

Waldenstrom Macroglobulinemia - Discontinued Products 197

Appendix 198

Methodology 198

Coverage 198

Secondary Research 198

Primary Research 198

Expert Panel Validation 198

Contact Us 198

Disclaimer 199

List of Tables

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016 10

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Waldenstrom Macroglobulinemia – Pipeline by AbbVie Inc, H2 2016 18

Waldenstrom Macroglobulinemia – Pipeline by Amgen Inc., H2 2016 19

Waldenstrom Macroglobulinemia – Pipeline by arGEN-X BV, H2 2016 20

Waldenstrom Macroglobulinemia – Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21

Waldenstrom Macroglobulinemia – Pipeline by Bayer AG, H2 2016 22

Waldenstrom Macroglobulinemia – Pipeline by BeiGene, Ltd., H2 2016 23

Waldenstrom Macroglobulinemia – Pipeline by Calithera Biosciences, Inc., H2 2016 24

Waldenstrom Macroglobulinemia – Pipeline by Celgene Corporation, H2 2016 25

Waldenstrom Macroglobulinemia – Pipeline by Genentech, Inc., H2 2016 26

Waldenstrom Macroglobulinemia – Pipeline by Gilead Sciences, Inc., H2 2016 27

Waldenstrom Macroglobulinemia – Pipeline by Hutchison MediPharma Limited, H2 2016 28

Waldenstrom Macroglobulinemia – Pipeline by IGF Oncology, LLC., H2 2016 29

Waldenstrom Macroglobulinemia – Pipeline by Incyte Corporation, H2 2016 30

Waldenstrom Macroglobulinemia – Pipeline by Juno Therapeutics Inc., H2 2016 31

Waldenstrom Macroglobulinemia – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 32

Waldenstrom Macroglobulinemia – Pipeline by Merck KGaA, H2 2016 33

Waldenstrom Macroglobulinemia – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 34

Waldenstrom Macroglobulinemia – Pipeline by Novartis AG, H2 2016 35

Waldenstrom Macroglobulinemia – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 36

Waldenstrom Macroglobulinemia – Pipeline by Portola Pharmaceuticals, Inc., H2 2016 37

Waldenstrom Macroglobulinemia – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38

Waldenstrom Macroglobulinemia – Pipeline by Vivolux AB, H2 2016 39

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 46

Number of Products by Stage and Route of Administration, H2 2016 48

Number of Products by Stage and Molecule Type, H2 2016 50

Waldenstrom Macroglobulinemia – Dormant Projects, H2 2016 196

Waldenstrom Macroglobulinemia – Discontinued Products, H2 2016 197

List of Figures

List of Figures

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 40

Number of Products by Top 10 Targets, H2 2016 42

Number of Products by Stage and Top 10 Targets, H2 2016 42

Number of Products by Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45

Number of Products by Routes of Administration, H2 2016 47

Number of Products by Stage and Routes of Administration, H2 2016 47

Number of Products by Molecule Types, H2 2016 49

Number of Products by Stage and Molecule Types, H2 2016 49


Discounts available for multiple report purchases.

+44 (0) 161 359 5414

Saved reports